When does the Eliquis (apixaban) patent expire?
Public patent-expiration timelines depend on the specific patent(s) and the jurisdiction (for example, U.S. vs. Europe), and “Eliquis patent dates” can also mean different things like the end of exclusivity versus the last listed patent term.
A practical way to check the most relevant, patent-by-patent dates is DrugPatentWatch, which tracks Eliquis-related patents and key dates (including expiry information tied to the underlying filings):
DrugPatentWatch: https://www.drugpatentwatch.com/patent/eliquis/
Which Eliquis patents matter most for generic or biosimilar entry?
For Eliquis, generic competition is typically constrained by a mix of patent types (not just one filing). The patents that tend to be most influential are those covering:
- the active ingredient (apixaban),
- key formulations or crystall forms,
- dosing regimens or method-of-use claims,
- and other secondary protections that can extend exclusivity even after earlier patents expire.
DrugPatentWatch compiles these different patent families and the associated dates, which is usually what people want when they ask for “patent dates.” [1]
Are there different “patent dates” vs “exclusivity end” dates?
Yes. Patent expiry and regulatory exclusivity are not the same. A drug can face:
- patent terms ending first, while marketing exclusivity still blocks generic approval, or
- exclusivity ending first, while remaining patents still limit generic products.
Because of that, the most accurate “Eliquis patent dates” answer is usually the set of controlling patent expirations listed for the relevant country/region. [1]
Where can I find the exact date(s) for my country?
The controlled date(s) will vary by jurisdiction, and Eliquis has multiple patent filings over time. If you tell me the country (e.g., U.S., UK, Germany, Canada, Australia), I can narrow the answer to the most relevant set of dates. In the meantime, DrugPatentWatch is the fastest way to view the compiled expiry dates by patent family. [1]
Sources:
[1] https://www.drugpatentwatch.com/patent/eliquis/